我要投票 康达在医疗器械行业中的票数:135
· 外 推 电 报 ·
2025-02-23 18:08:41 星期日

【康达是哪个国家的品牌?】

康达是什么牌子?「康达」是 上海康达医疗器械集团股份有限公司 旗下著名品牌。该品牌发源于上海市,由创始人郭 * 阳在2006年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康达品牌出海!通过在本页面挂载康达品牌的产品链接和联系邮箱,可以提高康达产品曝光!跨境电商爆单神器,目前只要100元/年哦~

上海康达医疗器械集团股份有限公司,通过自身的专业和敬业,对市场的敏锐触觉,对企业的精细化管理,向广大医院客户提供具性价比的产品,以“知您想,为您想”(WE THINK ABOUT YOUR THINK)为企业精神,从各个角度深刻发掘,客户群体、企业自身和市场行业的真正需求并以之为前进方向与动力。

上海康达医疗器械集团股份有限公司是一个多国际、国内品牌医疗设备服务供应商,研发、制造、生产、销售、服务多环节全面涉及,除了负责销售和服务的母公司外,还有五家负责生产制造的子公司。公司总部设在上海,并在多个中心城市设立了办事处和售后分支服务机构。

产品结构

目前分为两大事业部:影像产品事业部:分为七条不同产品线:分别为CT、Mr产品线、多功能X线机产品线、直接数字化摄影系统(DR)产品线、乳腺X线机产品线、C形臂产品线、数字化升级产品线和移动数字X线机产品线。

口腔事业部:分为四个产品线:分别为口腔影像设备产品线、口腔综合治疗台产品线、口腔技工设备产品线以及口腔高值耗材产品线。康达是一个多品牌多层次的设备供应商,每条产品线都有适合不同用户的产品。

经营之道

康达顺应改革开放的契机,通过分析国内市场,认为随着中国医疗卫生产业的不断发展,未来的医用设备市场走向规范和成熟。公司选择同具有强大专业制造能力的生产型企业合作,把并不熟知的国际专业品牌引进中国。

产业进程

从2008年开始,康达开始推进产业化进程,并购新黄浦医疗器械公司以打造影像设备生产平台,并购森德科技发展公司形成口腔治疗设备产业链。近几年,康达通过收购、参股的方式,在产业化之路坚定的前进,目前康达旗下已经聚集了六家子公司。康达产业集群正在逐步形成。

市场口碑

经过十多年,康达售出各类大型医学影像设备和口腔设备10000多台套,终端客户9000多家,产品分布全国各个省市自治区,质量广受好评,通过公司的市场运作和推广,过去不为中国用户所知的品牌都已经渐渐成熟。而合作伙伴和终端客户的信心也随着公司的进步而不断加强。

4S中心

康达未来的发展,依然是贯彻既定的营销策略,全新的上海国际医学园区总部,让公司以一个全新的姿态面对国际国内的合作伙伴与潜在合作伙伴。康达创造性的将大规模综合服务模式引入医疗器械行业,斥资人民币两亿元,建立全新的4S产品中心,面积达到两万六千平方,将融合展示(SHOW)、销售(SALES)、服务(SERVICE)、配件(SPARE)四大功能于一体,形成全新的产品生产营销模式。


英文翻译:Shanghai Kangda Medical Equipment Group Co., Ltd. provides cost-effective products to hospital customers through its own professional and dedicated work, keen sense of market, refined management of enterprises, takes "knowing what you want, thinking for you" as the enterprise spirit, and deeply explores the real customer groups, enterprises and market industries from all angles Demand and take it as the direction and driving force. Shanghai Kangda Medical Equipment Group Co., Ltd. is a multi international and domestic brand medical equipment service provider, which is involved in R & D, manufacturing, production, sales and service. In addition to the parent company responsible for sales and service, there are five subsidiaries responsible for production and manufacturing. Headquartered in Shanghai, the company has set up offices and after-sales branches in several central cities. At present, the product structure is divided into two business divisions: image product business division: it is divided into seven different product lines: CT, Mr product line, multi-functional X-ray machine product line, direct digital photography system (DR) product line, breast X-ray machine product line, C-arm product line, digital upgrade product line and mobile digital X-ray machine product line. Oral business department: it is divided into four product lines: oral imaging equipment product line, oral comprehensive treatment platform product line, oral technician equipment product line and oral high value consumables product line. Kangda is a multi brand and multi-level equipment supplier, each product line has products suitable for different users. According to the opportunity of reform and opening up, through analyzing the domestic market, Kangda believes that with the continuous development of China's medical and health industry, the future medical equipment market will be standardized and mature. The company chooses to cooperate with production-oriented enterprises with strong professional manufacturing capacity to introduce international professional brands that are not well known to China. Since 2008, Kangda has been promoting the industrialization process, acquiring new Huangpu medical equipment company to build a production platform for imaging equipment, and acquiring Zehnder technology development company to form the industrial chain of dental treatment equipment. In recent years, Kangda has made firm progress on the road of industrialization through acquisition and equity participation. At present, Kangda has gathered six subsidiaries. Kangda Industrial Cluster is gradually forming. After more than ten years of market reputation, Kangda has sold more than 10000 sets of various large-scale medical imaging equipment and dental equipment, more than 9000 end customers, products are distributed in various provinces and autonomous regions of the country, and the quality is widely praised. Through the company's market operation and promotion, the brands that were not known by Chinese users in the past have gradually matured. And the confidence of partners and end-users has been strengthened with the progress of the company. The future development of Kangda in 4S center is still to implement the established marketing strategy and the brand-new headquarters of Shanghai International Medical Park, so that the company can face the international and domestic partners and potential partners with a brand-new attitude. Kangda creatively introduced the large-scale comprehensive service mode into the medical device industry, invested 200 million yuan, and established a brand-new 4S product center, covering an area of 26000 square meters. It integrated the four functions of show, sales, service and spare, forming a brand-new product production and marketing mode.

本文链接: https://www.waitui.com/brand/53741c7bf.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

9分钟前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

9分钟前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

9分钟前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

9分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

9分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询